Archive for July 8th, 2011

Updates from Thursday – ALKS AMLN YMI EXEL AMRN IDRA

Jul 08, 2011 No Comments by

Alkermes, Inc. (NASDAQ: ALKS) on Thursday announced that topline results from a Phase 2 clinical study of ALKS 33 in the treatment of binge eating disorder did not meet its efficacy endpoint and is likely to discontinue further studies in the binge eating indication. It also mentioned together with Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli […]

Daily News Read more